New antimicrobial agents for the treatment of Gram-positive bacterial infections

被引：74

作者：

Aksoy, D. Y. ^{[2
]}

Unal, S. ^{[1
]}

机构：

[1] Hacettepe Univ, Fac Med, Dept Internal Med, Infect Dis Sect, TR-06100 Ankara, Turkey

[2] Hacettepe Univ, Dept Internal Med, TR-06100 Ankara, Turkey

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2008年 / 14卷 / 05期

关键词：

ceftobiprole; daptomycin; linezolid; quinupristin-dalfopristin; review; tigecycline;

D O I：

10.1111/j.1469-0691.2007.01933.x

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Since the 1970s, resistance to antimicrobial agents has become an escalating problem. In the last 25 years, treatment of infections caused by Gram-positive bacteria has been more problematical than ever, with infections being caused by multidrug-resistant organisms, particularly methicillin-resistant staphylococci, penicillin- and erythromycin-resistant pneumococci, and vancomycin-resistant enterococci. There is a continuing effort in the pharmaceutical industry to develop new antimicrobial agents for the treatment of resistant infections. Linezolid, quinupristin-dalfopristin, daptomycin, tigecyline, new glycopeptides and ceftobiprole are the main agents recently introduced or under clinical development. This review summarises their major properties, the results of recent studies with these agents, and future treatment possibilities.

引用

页码：411 / 420

页数：10

共 96 条

[1] Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations [J].

Akins, RL ;

Rybak, MJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :454-459

[2]

AKSOY DY, 2007, ANTIBIOTIC POLICIES, P113

[3] Antibiotics for treatment of resistant gram-positive coccal infections [J].

Hossam Al-Tatari ;

Nahed Abdel-Haq ;

Pimpanada Chearskul ;

Basim Asmar .

The Indian Journal of Pediatrics, 2006, 73 (4) :323-334

[4] Mechanism of action of oritavancin and related glycopeptide antibiotics [J].

Allen, NE ;

Nicas, TI .

FEMS MICROBIOLOGY REVIEWS, 2003, 26 (05) :511-532

[5] MRSA - the tip of the iceberg [J].

Appelbaum, PC .

CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 :3-10

[6] The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections [J].

Arbeit, RD ;

Maki, D ;

Tally, FP ;

Campanaro, E ;

Eisenstein, BI .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1673-1681

[7] The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data [J].

Babinchak, T ;

Ellis-Grosse, E ;

Dartois, N ;

Rose, GM ;

Loh, E .

CLINICAL INFECTIOUS DISEASES, 2005, 41 :S354-S367

[8] Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients [J].

Bishop, E ;

Melvani, S ;

Howden, BP ;

Charles, PGP ;

Grayson, ML .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (04) :1599-1602

[9] Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin [J].

Bogdanovich, T ;

Ednie, LM ;

Shapiro, S ;

Appelbaum, PC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (10) :4210-4219

[10] Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection [J].

Boylan, CJ ;

Campanale, K ;

Iversen, PW ;

Phillips, DL ;

Zeckel, ML ;

Parr, TR .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1700-1706

← 1 2 3 4 5 6 7 8 9 10 →